Epidemiology and factors associated with drug hepatotoxicity in patients at IPS Universitaria Clínica León XIII

Pharmaceutical Promotion and Prevention Group (P&PF)0 个研究点开始时间: 2017年4月27日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Patients older than 18 years.
•2. Presumptive identification of hepatotoxicity: patients who, upon admission to the emergency room or during hospitalization, are assigned an increase in alanine aminotransferase values greater than 3 times and/or alkaline phosphatase higher than 2 times the upper limit of normal, and the physician in charge considers that the stay in the institution is superior to 48-72 hours, due to the need to follow the reduction or elevation of the altered values and confirm the possible hepatotoxicity.
•3. Patients or caregivers who authorize their participation in the study through the signing of informed consent.

•1. Patients with an increase in ALT values greater than 3 times the ULN and / or ALP higher than 2 times the ULN for more than 6 months.
•2. Patients with acute coronary syndrome.
•3. Patients with terminal disease.
•4. Patients with some type of neoplasm under treatment.
•5. Patients with intoxications
•6. Patients with alcohol consumption greater than 20 g / day in women and greater than 40 g/day in men.

发起方

Pharmaceutical Promotion and Prevention Group (P&PF)